To build or buy? Examining the pros of building vs. buying a biorepository facility


Biorepositories play a pivotal role in advancing therapies such as cell and gene therapies by collecting, processing, and storing biospecimens that are critical to drug research, development, and manufacturing. These facilities manage a wide range of biospecimens at subzero temperatures, including tissues, blood, DNA, RNA, and cells, which are essential for understanding disease mechanisms, identifying potential targets for therapy, and developing novel treatment approaches. Biorepositories ensure the integrity, traceability, and availability of these materials, accelerating the translation of scientific discoveries into clinical applications.

When contemplating the establishment of a biorepository facility, biotechnology and pharmaceutical companies must carefully weigh the advantages of building versus buying. Constructing a facility from scratch offers the opportunity to tailor every aspect of the infrastructure to the specific requirements of the organization and the therapies it supports. On the other hand, purchasing space in an existing biorepository presents several compelling advantages, including significant time and cost savings. Additionally, this approach eliminates the lengthy construction period and associated uncertainties, allowing organizations to accelerate market entry.

Our new article, “To build or buy? Examining the pros of building vs. buying a biorepository facility,” expands on these advantages and disadvantages, and explores why partnering with a CDMO might be the right choice.